Clinical treatment for hepatitis C reverses CYP2C19 inhibition (2021)
- Authors:
- USP affiliated authors: ROCHA, ADRIANA - FCFRP ; LANCHOTE, VERA LUCIA - FCFRP ; PIPPA, LEANDRO FRANCISCO - FCFRP
- Unidade: FCFRP
- DOI: 10.1111/bcp.14829
- Subjects: ANTIVIRAIS; CITOCROMO P-450; FLAVIVIRIDAE; HEPATITE C; HEPATITE CRÔNICA; FARMACOTERAPIA
- Keywords: CYP2C19; HCV treatment; Hepatitis C; Metabolic ratio; Omeprazole
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: West Sussex
- Date published: 2021
- Source:
- Título: British Journal of Clinical Pharmacology
- ISSN: 0306-5251
- Volume/Número/Paginação/Ano: v. 87, n. 10, p. 4013-4019, 2021
- Status:
- Artigo possui acesso gratuito no site do editor (Bronze Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
PIPPA, Leandro Francisco et al. Clinical treatment for hepatitis C reverses CYP2C19 inhibition. British Journal of Clinical Pharmacology, v. 87, n. 10, p. 4013-4019, 2021Tradução . . Disponível em: https://doi.org/10.1111/bcp.14829. Acesso em: 02 abr. 2026. -
APA
Pippa, L. F., Vieira, C. P., Caris, J. A., Rocha, A., Garcia, C. P., Rezende, R. E. F., & Lanchote, V. L. (2021). Clinical treatment for hepatitis C reverses CYP2C19 inhibition. British Journal of Clinical Pharmacology, 87( 10), 4013-4019. doi:10.1111/bcp.14829 -
NLM
Pippa LF, Vieira CP, Caris JA, Rocha A, Garcia CP, Rezende REF, Lanchote VL. Clinical treatment for hepatitis C reverses CYP2C19 inhibition [Internet]. British Journal of Clinical Pharmacology. 2021 ; 87( 10): 4013-4019.[citado 2026 abr. 02 ] Available from: https://doi.org/10.1111/bcp.14829 -
Vancouver
Pippa LF, Vieira CP, Caris JA, Rocha A, Garcia CP, Rezende REF, Lanchote VL. Clinical treatment for hepatitis C reverses CYP2C19 inhibition [Internet]. British Journal of Clinical Pharmacology. 2021 ; 87( 10): 4013-4019.[citado 2026 abr. 02 ] Available from: https://doi.org/10.1111/bcp.14829 - Suppression of CYP isoforms in patients with chronic hepatitis c before and after pharmacological treatment depends on the stage of hepatic fibrosis
- Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio
- Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia
- Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients
- Omeprazole inhibits preferentially the metabolism of the (+)-(S)-citalopram eutomer in healthy volunteers
- Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers
- Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers
- Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics
- Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta]
- UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003084938.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
